Monopar Therapeutics Inc (MNPR) Stock Price, Quote & News

Company Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imagi...

Industry: Biotechnology

Sector: Healthcare

Phone: 847 388 0349

Website: www.monopartx.com

Address:

1000 Skokie Boulevard, Suite 350, Wilmette, United States

Pipelinepivots Sep. 12 at 8:16 AM

Golden cross + micro float = pressure cooker. MITQ is starting to curl, and if volume hits with a headline… It won’t just run, it’ll gap. $MNPR $MODD $REVB $NAOV

0 · Reply

Pipelinepivots Sep. 12 at 7:58 AM

MITQ has one of the cleanest setups in small caps right now. ✔️ Golden cross forming ✔️ Micro float ✔️ Bottomed chart ✔️ No major eyes yet Just like $OCTO before it ran — all it needs is a spark. $MNMD $MNPR $XELA $GNS …

1 · Reply

RadioIsotope25 Sep. 11 at 2:23 PM

$MNPR $RADX

0 · Reply

JarvisFlow Sep. 9 at 11:00 AM

BTIG updates rating for Monopar Therapeutics ( $MNPR ) to Buy, target set at 87.

0 · Reply

RiseofTheApes Sep. 7 at 7:26 PM

$MNPR SKYQ has a massive squeeze setup and Looks like more people are finding this one. Reversing from bottom. $1+ very possible! Upcoming Crypto catalyst+News, its ready!

0 · Reply

RadioIsotope25 Sep. 5 at 7:44 PM

$RADX Monopar + Radiopharm $MNPR

0 · Reply

RadioIsotope25 Sep. 3 at 6:14 PM

$RADX Lantheus has spent $643 million on acquisitions past 12 months. Up to 12% ownership on Radiopharm Theranostics. Last entry point $11.70 per share in the first quarter. Market cap of RadX stills about at about 1/6th of their average take over value of $300 million. $MNPR $ATNM $CLRB

1 · Reply

JarvisFlow Sep. 3 at 4:50 PM

Raymond James updates rating for Monopar Therapeutics ( $MNPR ) to Strong Buy, target set at 80.

0 · Reply

RadioIsotope25 Sep. 2 at 11:48 PM

$RADX https://www.biospace.com/fda/fdas-new-radiopharma-guidance-a-greenlight-for-an-accelerating-space $LNTH $CATX $MNPR

1 · Reply

Takeover24 Sep. 2 at 6:23 PM

$CLNN Could this be the next $DRUG or $MNPR?

0 · Reply

Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Sep 3, 2025, 8:00 AM EDT - 10 days ago

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Aug 12, 2025, 8:00 AM EDT - 4 weeks ago

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Jun 11, 2025, 7:00 AM EDT - 3 months ago

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Jun 3, 2025, 7:00 AM EDT - 3 months ago

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

May 13, 2025, 8:00 AM EDT - 4 months ago

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

May 7, 2025, 2:30 AM EDT - 4 months ago

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

Jan 23, 2025, 1:10 PM EST - 8 months ago

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Dec 23, 2024, 2:23 PM EST - 9 months ago

Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways

Dec 20, 2024, 9:00 AM EST - 9 months ago

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Dec 5, 2024, 4:21 PM EST - 10 months ago

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Dec 3, 2024, 8:00 AM EST - 10 months ago

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 25, 2024, 7:53 PM EST - 10 months ago

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

Nov 8, 2024, 8:00 AM EST - 11 months ago

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Oct 30, 2024, 1:42 PM EDT - 11 months ago

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 9:15 PM EDT - 11 months ago

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Oct 28, 2024, 4:00 PM EDT - 11 months ago

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

Oct 28, 2024, 1:29 PM EDT - 11 months ago

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Oct 24, 2024, 1:18 PM EDT - 11 months ago

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

AZN

Oct 22, 2024, 8:00 AM EDT - 11 months ago

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

Oct 15, 2024, 8:00 AM EDT - 11 months ago

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

Aug 21, 2024, 8:00 AM EDT - 1 year ago

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Monopar and NorthStar Amend & Extend Collaboration

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces CFO Succession

May 9, 2024, 7:00 AM EDT - 1 year ago

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Mar 5, 2024, 7:00 AM EST - 1 year ago

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Feb 27, 2024, 7:00 AM EST - 1 year ago

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Feb 20, 2024, 8:00 AM EST - 1 year ago

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

Nov 9, 2023, 7:00 AM EST - 2 years ago

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

Oct 10, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

Jun 21, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Radiopharma Forum by the Lake 2023

Jun 14, 2023, 7:00 AM EDT - 2 years ago

Monopar to Participate in the Maxim Group's Healthcare Virtual Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

Mar 28, 2023, 7:00 AM EDT - 2 years ago

Monopar to Present at the Jefferies Radiopharma Innovation Summit

Mar 27, 2023, 5:00 PM EDT - 2 years ago

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

Mar 23, 2023, 7:00 AM EDT - 2 years ago

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

Pipelinepivots Sep. 12 at 8:16 AM

Golden cross + micro float = pressure cooker. MITQ is starting to curl, and if volume hits with a headline… It won’t just run, it’ll gap. $MNPR $MODD $REVB $NAOV

0 · Reply

Pipelinepivots Sep. 12 at 7:58 AM

1 · Reply

RadioIsotope25 Sep. 11 at 2:23 PM

$MNPR $RADX

0 · Reply

JarvisFlow Sep. 9 at 11:00 AM

BTIG updates rating for Monopar Therapeutics ( $MNPR ) to Buy, target set at 87.

0 · Reply

RiseofTheApes Sep. 7 at 7:26 PM

$MNPR SKYQ has a massive squeeze setup and Looks like more people are finding this one. Reversing from bottom. $1+ very possible! Upcoming Crypto catalyst+News, its ready!

0 · Reply

RadioIsotope25 Sep. 5 at 7:44 PM

$RADX Monopar + Radiopharm $MNPR

0 · Reply

RadioIsotope25 Sep. 3 at 6:14 PM

1 · Reply

JarvisFlow Sep. 3 at 4:50 PM

Raymond James updates rating for Monopar Therapeutics ( $MNPR ) to Strong Buy, target set at 80.

0 · Reply

RadioIsotope25 Sep. 2 at 11:48 PM

$RADX https://www.biospace.com/fda/fdas-new-radiopharma-guidance-a-greenlight-for-an-accelerating-space $LNTH $CATX $MNPR

1 · Reply

Takeover24 Sep. 2 at 6:23 PM

$CLNN Could this be the next $DRUG or $MNPR?

0 · Reply

maxD2016 Aug. 31 at 7:34 PM

$LNTH $RADX $MNPR $QQQ

0 · Reply

RadioIsotope25 Aug. 30 at 3:22 PM

Bigger market for RAD101 than prostate cancer. Lantheus just bought Octevy and evergreen for $250 million up front and market is smaller. Lantheus already owns 12% having bought more stock at $11.70 in the first quarter. Phase2b data for RAD101 due in September. https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-rad101-for-imaging-of-recurrent-brain-metastases $LNTH $RADX $MNPR

0 · Reply

RadioIsotope25 Aug. 29 at 12:52 PM

$RADX $CLRB $LNTH $ATNM $MNPR

1 · Reply

RadioIsotope25 Aug. 28 at 5:45 PM

Just turn into Monopar already Radiopharm Theranostics! $MNPR $RADX

1 · Reply

CryptoSenderX Aug. 28 at 9:09 AM

$REVB pay attention on this one Bulls $THAR I $ALLR I $MNPR I $DRUG 🪐

0 · Reply

uppalapatikc Aug. 25 at 5:37 PM

$MNPR How much more can this stock bleed, it has lost 34.5% in a month. What are your thoughts

0 · Reply

RadioIsotope25 Aug. 22 at 2:37 AM

$RADX Biotech’s with LU-177 drugs that were acquired. Radiopharm has a pipeline flush of them and ceo is ex- Novartis. $MNPR $LNTH $CLRB

1 · Reply

uppalapatikc Aug. 18 at 4:18 PM

$MNPR This is the second time in a week that it got rejected at the 36.30 mark.

0 · Reply

RadioIsotope25 Aug. 18 at 3:50 AM

$RADX Biotech Daily https://mcusercontent.com/2020b74e9b9a298e9cadee03b/files/86b90175-7040-d85a-e568-7d8751aa61b8/RAD_Aug_15_2025.pdf $MNPR $LNTH

0 · Reply

RadioIsotope25 Aug. 14 at 6:10 PM

$RADX Could turn into to Corbus or MNPR 2.0 with strong data this fall Tiny float $MNPR $CRBP

0 · Reply

JarvisFlow Aug. 13 at 8:59 PM

Chardan Capital has updated their rating for Monopar Therapeutics ( $MNPR ) to Buy with a price target of 60.

0 · Reply

uppalapatikc Aug. 13 at 3:39 PM

$MNPR Wow what the hell is happening here, lost all of yesterdays gain

0 · Reply

Market Cap	294.09M
Revenue (ttm)	0.00
Net Income (ttm)	-15.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,300
Avg Vol	35,216
Day's Range	N/A - N/A
Shares Out	6.17M
Stochastic %K	97%
Beta	1.20
Analysts	Strong Sell
Price Target	$72.00